Anna Szlachcic

Structure of a highly stable mutant of human fibroblast growth factor 1.

Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.

The structural basis of tail-anchored membrane protein recognition by Get3.

Two pentadehydropeptides with different configurations of the DeltaPhe residues.

Longer action means better drug: tuning up protein therapeutics.

Tailoring small proteins towards biomedical applications.

FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation.

Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.

Site-specific conjugation of fibroblast growth factor 2 (FGF2) based on incorporation of alkyne-reactive unnatural amino acid.

High-Yield Site-Specific Conjugation of Fibroblast Growth Factor 1 with Monomethylauristatin E via Cysteine Flanked by Basic Residues.

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1.

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection.

Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity.

FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1.